Form 8-K - Current report:
SEC Accession No. 0001558370-25-003542
Filing Date
2025-03-24
Accepted
2025-03-24 16:40:20
Documents
14
Period of Report
2025-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20250324x8k.htm   iXBRL 8-K 37938
2 EX-10.46 adap-20250324xex10d46.htm EX-10.46 73720
  Complete submission text file 0001558370-25-003542.txt   248362

Data Files

Seq Description Document Type Size
3 EX-101.SCH adap-20250324.xsd EX-101.SCH 3504
4 EX-101.LAB adap-20250324_lab.xml EX-101.LAB 15972
5 EX-101.PRE adap-20250324_pre.xml EX-101.PRE 10791
16 EXTRACTED XBRL INSTANCE DOCUMENT adap-20250324x8k_htm.xml XML 4916
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 25764662
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)